Literature DB >> 27347562

Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension.

Fei Liu1, Christina Mallarino Haeger2, Paul B Dieffenbach2, Delphine Sicard3, Izabela Chrobak4, Anna Maria F Coronata2, Margarita M Suárez Velandia2, Sally Vitali5, Romain A Colas6, Paul C Norris6, Aleksandar Marinković1, Xiaoli Liu2, Jun Ma2, Chase D Rose5, Seon-Jin Lee7, Suzy A A Comhair8, Serpil C Erzurum8, Jacob D McDonald4, Charles N Serhan6, Stephen R Walsh9, Daniel J Tschumperlin10, Laura E Fredenburgh2.   

Abstract

Pulmonary arterial (PA) stiffness is associated with increased mortality in patients with pulmonary hypertension (PH); however, the role of PA stiffening in the pathogenesis of PH remains elusive. Here, we show that distal vascular matrix stiffening is an early mechanobiological regulator of experimental PH. We identify cyclooxygenase-2 (COX-2) suppression and corresponding reduction in prostaglandin production as pivotal regulators of stiffness-dependent vascular cell activation. Atomic force microscopy microindentation demonstrated early PA stiffening in experimental PH and human lung tissue. Pulmonary artery smooth muscle cells (PASMC) grown on substrates with the stiffness of remodeled PAs showed increased proliferation, decreased apoptosis, exaggerated contraction, enhanced matrix deposition, and reduced COX-2-derived prostanoid production compared with cells grown on substrates approximating normal PA stiffness. Treatment with a prostaglandin I2 analog abrogated monocrotaline-induced PA stiffening and attenuated stiffness-dependent increases in proliferation, matrix deposition, and contraction in PASMC. Our results suggest a pivotal role for early PA stiffening in PH and demonstrate the therapeutic potential of interrupting mechanobiological feedback amplification of vascular remodeling in experimental PH.

Entities:  

Year:  2016        PMID: 27347562      PMCID: PMC4918638          DOI: 10.1172/jci.insight.86987

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  77 in total

1.  Defined three-dimensional microenvironments boost induction of pluripotency.

Authors:  Massimiliano Caiazzo; Yuya Okawa; Adrian Ranga; Alessandra Piersigilli; Yoji Tabata; Matthias P Lutolf
Journal:  Nat Mater       Date:  2016-01-11       Impact factor: 43.841

Review 2.  Tissue cells feel and respond to the stiffness of their substrate.

Authors:  Dennis E Discher; Paul Janmey; Yu-Li Wang
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

Review 3.  Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.

Authors:  Irene M Lang; Sean P Gaine
Journal:  Eur Respir Rev       Date:  2015-12

4.  Extraction of pulmonary vascular compliance, pulmonary vascular resistance, and right ventricular work from single-pressure and Doppler flow measurements in children with pulmonary hypertension: a new method for evaluating reactivity: in vitro and clinical studies.

Authors:  Craig E Weinberg; Jean R Hertzberg; D Dunbar Ivy; K Scott Kirby; K Chen Chan; Lilliam Valdes-Cruz; Robin Shandas
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

Review 5.  Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy.

Authors:  M Delcroix; K Spaas; R Quarck
Journal:  Eur Respir Rev       Date:  2009-12

6.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

Authors:  B W Christman; C D McPherson; J H Newman; G A King; G R Bernard; B M Groves; J E Loyd
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

7.  Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility.

Authors:  Laura E Fredenburgh; Jun Ma; Mark A Perrella
Journal:  Trends Cardiovasc Med       Date:  2009-02       Impact factor: 6.677

8.  Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents.

Authors:  Chabha Benyahia; Gulsev Ozen; Nelson Orie; Agatha Ledwozyw; Liliane Louedec; Fangfang Li; Amira M Senbel; Adam Silverstein; Claire Danel; Dan Longrois; Lucie H Clapp; Xavier Norel; Gökçe Topal
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-09-08       Impact factor: 3.072

9.  Pulmonary vascular wall stiffness: An important contributor to the increased right ventricular afterload with pulmonary hypertension.

Authors:  Zhijie Wang; Naomi C Chesler
Journal:  Pulm Circ       Date:  2011 Apr-Jun       Impact factor: 3.017

10.  Micro-mechanical characterization of lung tissue using atomic force microscopy.

Authors:  Fei Liu; Daniel J Tschumperlin
Journal:  J Vis Exp       Date:  2011-08-28       Impact factor: 1.355

View more
  33 in total

1.  Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension.

Authors:  Krishna C Penumatsa; Deniz Toksoz; Rod R Warburton; Mousa Kharnaf; Ioana R Preston; Navin K Kapur; Chaitan Khosla; Nicholas S Hill; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Tethering transforming growth factor β1 to soft hydrogels guides vascular smooth muscle commitment from human mesenchymal stem cells.

Authors:  Yonghui Ding; Richard Johnson; Sadhana Sharma; Xiaoyun Ding; Stephanie J Bryant; Wei Tan
Journal:  Acta Biomater       Date:  2020-01-23       Impact factor: 8.947

3.  Bone Marrow-Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism.

Authors:  Nathaniel C Bloodworth; Cynthia R Clark; James D West; J Caleb Snider; Christa Gaskill; Sheila Shay; Christine Scott; Julie Bastarache; Santhi Gladson; Christy Moore; Reid D'Amico; Evan L Brittain; Harikrishna Tanjore; Timothy S Blackwell; Susan M Majka; W David Merryman
Journal:  Circ Res       Date:  2018-12-07       Impact factor: 17.367

4.  Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.

Authors:  Paul B Dieffenbach; Christina Mallarino Haeger; Anna Maria F Coronata; Kyoung Moo Choi; Xaralabos Varelas; Daniel J Tschumperlin; Laura E Fredenburgh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-06-22       Impact factor: 5.464

Review 5.  Matrix biomechanics and dynamics in pulmonary fibrosis.

Authors:  Andrew J Haak; Qi Tan; Daniel J Tschumperlin
Journal:  Matrix Biol       Date:  2017-12-21       Impact factor: 11.583

6.  Pulmonary pulse wave transit time is associated with right ventricular-pulmonary artery coupling in pulmonary arterial hypertension.

Authors:  Kurt W Prins; E Kenneth Weir; Stephen L Archer; Jeremy Markowitz; Lauren Rose; Marc Pritzker; Richard Madlon-Kay; Thenappan Thenappan
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

7.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

8.  Aging and anatomical variations in lung tissue stiffness.

Authors:  Delphine Sicard; Andrew J Haak; Kyoung Moo Choi; Alexandria R Craig; Laura E Fredenburgh; Daniel J Tschumperlin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-02-22       Impact factor: 5.464

Review 9.  Tissue-informed engineering strategies for modeling human pulmonary diseases.

Authors:  Kolene E Bailey; Michael L Floren; Tyler J D'Ovidio; Steven R Lammers; Kurt R Stenmark; Chelsea M Magin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-11-21       Impact factor: 5.464

10.  Biomimetic soft fibrous hydrogels for contractile and pharmacologically responsive smooth muscle.

Authors:  Yonghui Ding; Xin Xu; Sadhana Sharma; Michael Floren; Kurt Stenmark; Stephanie J Bryant; Corey P Neu; Wei Tan
Journal:  Acta Biomater       Date:  2018-05-16       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.